Johnson & Johnson Diabetes Drug Approved by FDA

The Food and Drug Administration has granted approval to Invokana, a Type 2 diabetes drug manufactured by a unit of Johnson & Johnson (NYSE: JNJ  ) . The drug is part of a new class of treatments known as SGLT2 inhibitors aimed at lowering blood sugar in patients with that form of the disease.

With its approval, the FDA has mandated that five postmarketing studies be conducted for the drug, which was developed by J&J subsidiary Janssen Pharmaceuticals.

Type 2 is by far the most common variety of diabetes, affecting roughly 24 million people. According to the FDA, it comprises more than 90% of the diabetes cases diagnosed in this country.


Read/Post Comments (0) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2338129, ~/Articles/ArticleHandler.aspx, 10/25/2014 8:07:27 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement